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Pneumonia still represents a major disease burden in children in industrialized countries [1] . In all, 20%-60% of cases of community-acquired pneumonia (CAP) are thought to be pneumococcus-related, but only a small proportion of pneumonia is diagnosed as pneumococcal in clinical practice [2] . Implementation of 7-valent pneumococcal conjugate vaccine (PCV7) has markedly reduced the incidence of pneumonia in several countries, mainly in children younger than 2 years [3] [4] [5] [6] .
However, some studies have reported an increase in CAP with empyema in children aged >5 years old [7, 8] . In 2010, the French authorities recommended routine vaccination with 13-valent pneumococcal conjugate vaccine (PCV13), replacing PCV7 at 2, 4, and 11-12 months of age [9] . During the 1-year transition period, for children younger than 2 years, the recommendation was to replace PCV7 with PCV13 at any point in the schedule to complete the immunization series. During the considered period, the vaccination coverage by PCV7 and PCV13 was good (92%) for children younger than 2 years, but no catch-up was recommended for children aged 2-5 years, except for children at risk of invasive pneumococcal disease [10] . After PCV7 implementation, the serotypes 1, 3, 7F, and 19A were the most predominant in documented pneumococcal pneumonia and empyema in children. Because those serotypes were included in PCV13 (PCV7 serotypes with the addition of the new serotypes: 1, 3, 5, 6A, 7F, 19A), a strong additional impact of this new PCV on the epidemiology of these diseases was expected but not yet demonstrated [11] .
To assess the impact of PCV13 implementation, the Pediatric Infectious Diseases Group of the French Pediatric Society established an active surveillance network of CAP in pediatric emergency departments (PEDs) of 8 hospitals across France in 2009. We chose PEDs because in these settings, chest radiography is frequently performed when pneumonia is suspected and biological testing is frequently performed.
Here we provide epidemiological data of pneumococcal CAP in French PEDs before and after the implementation of PCV13 in France, with early information on the impact of PCV13 on CAP in children. We enrolled all patients between the ages of 1 month and 15 years with chest radiography-confirmed CAP in the PEDs. CAP was defined by the association of fever and chest radiograph showing consolidation and/or pleural effusion, diagnosed by pediatrician and confirmed by a pediatric radiologist [12] . The following data were collected: age, sex, risk factors for invasive pneumococcal disease, presence of pleural effusion, clinical data, biological results including C-reactive protein (CRP) and/or procalcitonin (PCT) level if tested, admission or discharge, treatment, and short-term outcome. No specific action was taken to standardize patient management among the 8 PEDs or among physicians in each hospital.
MATERIALS AND METHODS

This
Laboratory-confirmed pneumococcal CAP (P-CAP) was defined by at least 1 of the following 3 conditions: (1) blood or pleural culture positive for Streptococcus pneumoniae, (2) pneumococcal polymerase chain reaction (PCR)-positive results on pleural sample, or (3) pneumococcal antigen positive on pleural sample (Binax, Portland, Oregon). Isolates were serotyped at the National Pneumococcal Reference Center by the capsular swelling method with commercial antisera (Statens Serum Institut, Copenhagen, Denmark). Susceptibility of S. pneumoniae isolates to penicillin G was determined by minimum inhibitory concentrations (MICs) by the agar-dilution method. Isolates were classified as penicillin susceptible (MIC ≤ 0.06 µg/mL), intermediate resistant (MIC = 0.12-1.0 µg/mL), or fully penicillin resistant (MIC ≥ 2 µg/mL) according to the Clinical and Laboratory Standards Institute [13] . For the purpose of this study, the term "pyogenic CAP" referred to laboratory-confirmed bacterial pneumonia caused by S. pneumoniae, Staphylococcus aureus, or group A Streptococcus (GAS). pleural effusion were S. pneumoniae, n = 102; S. aureus, n = 16; and GAS, n = 11. Pyogenic CAP confirmed by any microbiological method ( pleural or blood culture, antigen detection, and PCR) was diagnosed in 164 of 5645 cases (2.9%) ( Figure 1 ). Among these cases, 136 were classified as P-CAP. Patients' clinical characteristics and biological data are shown in Table 1 . Data on penicillin susceptibility were available for 54 S. pneumoniae strains: 70.3% were penicillin susceptible, 16.7% penicillin intermediate, and 13% fully penicillin resistant (all belonging to serotype 19A).
Statistical Analysis
RESULTS
Global Epidemiological Data
CAP Analysis by Study Period
The number of PED visits increased during the study period (4.5%): 311 476 for the first year, 316 304 for the second, and 325 503 for the third. The distribution of CAP cases by age and period is shown in Table 2 . Cases of CAP decreased by 16% between the pre-PCV13 period (n = 1725) and post-PCV13 period (n = 2060). This decrease was highest for infants (≤2 years old) with a 32% decrease (P < 10 −3 ; CochranArmitage test) in the same periods. The proportion of CAP patients with CRP level >120 mg/dL and PCT level >4 ng/mL decreased from 41.3% to 29.7% and from 40.1% to 27.3%, respectively (Table 2) . Similarly, the number of CAP patients with pleural effusion and P-CAP decreased by 53% (P < 10 −3 ) and 63% (P = 10 −3 ; both Cochran-Armitage test) ( Table 2) . These decreasing trends were amplified if the data were expressed per 1000 PED visits. The rate of CAP cases per 1000 visits decreased by 20% between the pre-PCV13 period (6.61‰) and post-PCV13 period (5.29‰) (P < 10 −3 ;
Cochran-Armitage test; Supplementary Table 2 ). This trend was highest for infants with a 35% decrease (P < 10
Cochran-Armitage test) in the same period. Similarly, the rate of CAP cases per 1000 visits with pleural effusion and P-CAP decreased by 55% (P < 10 −3 ) and 64% (P < 10 −3 ; both Cochran-Armitage test), respectively. Among the 82 P-CAP cases diagnosed by culture (from blood or pleural fluid), a serotype was identified in 62 isolates; the distribution by study period is in Table 3 . PCV7 serotypes were identified in only 2 patients during the 3 periods. Additional PCV13 serotypes were predominant in 51 isolates (82%), but their number decreased by 74%, from 27 to 7 cases, between the pre-and post-PCV13 periods. Serotype 1 was predominant, accounting for 27 cases, and decreased from 12 to 5 cases between the pre-and post-PCV13 periods. Serotype 19A was the second most frequent (n = 13) and decreased from 8 to 1 between the periods. Serotype 1 was recovered mainly in children older than 5 years and serotype 19A in children <2 years of age.
Non-PCV13 serotype cases did not increase throughout the study (3 isolates in each study period; Table 3 ).
A single case of PCV13 vaccine failure (serotype 19A CAP complicated by pleural effusion) occurred in an 11-month-old infant without an underlying condition who had received 2 doses of PCV13 at 3 and 6 months of age. Extensive immunological exploration did not reveal any immunodeficiencies. The patient recovered without sequelae and remains well >1 year after the disease.
Seven patients died, except for 2 patients (1 with Down syndrome and heart disease and 1 with sickle-cell disease); the 5 others did not have known immunodeficiency before admission. Their ages ranged from 8 months to 9 years. None had Abbreviations: CAP, community-acquired pneumonia; CRP, C-reactive protein; ICU, intensive care unit; IPD, invasive pneumococcal disease; P-CAP, pneumococcal community-acquired pneumonia; PCT, procalcitonin; Q1-Q3, quartile 1 to 3; SD, standard deviation. pleural effusion. In 2009, 2 children with concomitant influenza H1N1 infection died. In 2 cases of death, a serotype was identified (23A and 33F). To document that case ascertainment did not change over time, we compared hospitalized-enrolled patients to CAP patients hospitalized in the 8 centers identified through the French hospital system's medico-administrative database (Programme de medicalisation des systèmes d'information). Good correlation was observed between the 2 sets of data.
DISCUSSION
To assess the impact of PCV13 in France, we conducted a prospective observational study of CAP in 8 French PEDs, representing >950 000 PED visits during a 3-year period. This study is the largest among published series of pneumonia in children. It is the first to demonstrate an additional impact of PCV13 on CAP in children: 2 years after the transition from PCV7 to PCV13 (even without a national catch-up program in children aged 2-5 years), significant reductions were noted in frequency of CAP in children younger than 2 years (−32%), CAP with pleural effusion (−53%), P-CAP (−63%), and P-CAP due to PCV13 serotypes (−74%). The decrease reached 17% in children aged 2-5 years, even though an extensive catch-up program has not been recommended. All these results are consistent and suggest a strong impact of PCV13 on pediatric CAP cases.
For children older than 5 years, the slight increase in CAP (Table 2) is probably due to the increase in number of PED visits, because the evolution of CAP according to 1000 PED visits does not increase significantly throughout the study's 3 periods (P = .477, Supplementary Table 2) . However, pleural effusion in children older than 5 years may be less often pneumococcal and more often caused by other microorganisms [4] . In addition, each study period was 1 year only, and thus, year-to-year fluctuations could be observed.
Furthermore, we showed a marked decrease in proportion of CAP with CRP level >120 mg/dL (−28%) and CAP with PCT level >4 ng/mL (−32%) [14] . CRP and PCT may be reliable markers of bacterial infection, particularly pneumococcal infection, but they are probably not sufficiently specific [15] . However, these markers could be considered complementary indicators reinforcing the case primarily based on microbiological data.
The serotype distribution confirms the predominance of the 6 additional PCV13 serotypes, which accounted for 82% of isolates, especially in the pre-PCV13 period, and a low rate of PCV7 serotype isolates (3.2%). These results are in line with previous studies of pneumococcal serotype distribution in childhood empyema in the PCV7 era [7, 16, 17] . The number of PCV13 serotypes decreased by 74% between the pre-and post-PCV13 periods, which support a strong impact of the vaccine. Another strength of the study is that serotype information is usually not available in post-PCV13 published studies [2] .
Serotype 1 was the leading serotype, with 27 isolates (44%), but decreased from 12 to 5 cases during the study period. Serotype 1 was mainly recovered in children older than 5 years, which suggests, in the absence of a catch-up program in France, an indirect protection of PCV13, but this decrease could also be due to a secular trend. However, serotype 1 remained the most frequent serotype in the post-PCV13 period (50% [5/10] of isolates). Serotype 19A was the second most frequent serotype, with 13 isolates (21%), which is in line with studies performed in Europe and the United States [16, 18, 19] . Serotype 19A cases decreased during the study period, mainly in infants, which suggests a direct protective effect of PCV13.
We observed no trend in replacement; indeed non-PCV13 isolates were sporadic and equally distributed (only 1 isolate for each serotype).
The 8 PEDs participating in the study represented 9% of all PED annual visits in France [20, 21] . Considering the high number of patients enrolled and the inclusion of both secondary and tertiary PED centers, our data probably reflect features of CAP in all French PEDs and provide reliable information about pneumococcal serotypes involved in CAP in France. Our study has several limitations. The first is the relatively low proportion of CAP among the PEDs visits (0.59%), which is lower than the 2.4% recently described for children with pneumonia in US PEDs [11] and the 2.1% described by Neuman et al [22] . However, our inclusion criteria were more restrictive. Only febrile patients with chest radiographic confirmation of CAP were included, not just patients with a CAP diagnosis code. This fact is related to the 32% hospitalization rate in our children (Table 1) as compared with the 26% rate in US PEDs [11] , which suggests more stringent diagnosis criteria for pneumonia in our study. Moreover, CAP was clinically diagnosed in US PEDs, and only 76% of suspected cases had a chest radiograph in one study [23] . Therefore, the definition of CAP cases has a direct impact on the number of included patients in studies.
The second limitation is the short duration of the observation period (3 years), which is probably too short to assess the full impact of PCV13. The full impact of PCV7 on hospitalization for pneumonia was described by Griffin et al 7 years after the vaccine's introduction [6] . Nevertheless, we have shown a 32% decrease in CAP cases in children younger than 2 years, despite a short period of observation and the absence of a catch-up program in France. Our postlicense observational study will continue to monitor changes in frequency of P-CAP linked to mass PCV13 vaccination in France and consider potential serotype replacement [24] .
The third limitation is the observational design of the study. We cannot rule out a sampling bias between and within centers. During the study, participating physicians were encouraged to not change their practice, including test utilization, and no other potential interfering intervention such as routine influenza vaccination or change in antibiotic policy was implemented. Although not all of our patients underwent testing for CRP, PCT and blood cultures, test utilization was higher in our study than in the recently described US PED study: 46.3% vs 7.5% CRP testing and 32.1% vs 27.9% blood-culture testing [23] . Systematic CRP and PCT testing would allow for a closer estimate of the PCVs efficacy [25] . Moreover in PEDs, visits related to CAP with the most severe presentation seemed to have higher test utilization [23] .
The last limitation is the low rate of bacteriologic documentation and is due to the low rate of positive blood cultures in our study (4.0%). Even if systematic testing with blood culture could increase bacteriological documentation, the low rate of positive results does not speak to such a strategy.
However, this rate is consistent with the prevalence of bacteremia recently estimated at 2.1% in a cohort of CAP diagnosed in a PED setting [26] . The rate of positive bacterial identification in CAP patients with pleural effusion was also low (129/365 [35.3%]) because only 145 (39.7%) pleural samples were obtained. Of note, molecular analysis (ie, PCR and/or pneumococcal antigen detection) improved the P-CAP diagnosis in this group of patients [7] . We did not use molecular-based methods for the diagnosis of pneumococcal invasive disease in blood, which seem to be promising [27] . However, these methods still feature low specificity, especially in children [27] .
CONCLUSIONS
This is the first study, to our knowledge, to suggest a strong impact on CAP cases after PCV13 implementation, following that of PCV7; CAP cases decreased significantly in 8 French PEDs after PCV13 implementation. Moreover, this reduction was maximal in cases most likely due to S. pneumoniae, such as P-CAP and CAP with pleural effusion. Children younger than 2 years seem to have benefited most in this reduction; further reductions are expected with the full immunization of more children and an optimized herd protection. Continued surveillance and other studies will clarify the PCV13 impact as well as the emergence of any replacement non-PCV13 serotypes in CAP.
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